IFM 4490
Alternative Names: IFM-4490Latest Information Update: 10 Jan 2023
At a glance
- Originator IFM therapeutics
- Developer IFM Due
- Class Small molecules; Vascular disorder therapies
- Mechanism of Action CGAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Vascular disorders
Most Recent Events
- 04 Jan 2023 Early research in Inflammation in USA (unspecified route)
- 10 Nov 2022 Pharmacodynamics data from research phase presented at the American College of Rheumatology Convergence (ACR-2022)
- 05 Sep 2019 IFM Therapeutics enters into a collaboration with Novartis for the the cGAS/STING antagonists